Nicotinic acid: The broad-spectrum lipid drug. A 50th anniversary review

Journal of Internal Medicine

Volumn 258, Issue 2, 2005, Pages 94-114

  Carlson, Lars A ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Coronary heart disease; Free fatty acids; HDL; LDL; Lp(a); Nicotinic acid; VLDL

Indexed keywords

CHOLESTEROL; COLESTIPOL; COLESTYRAMINE; FATTY ACID; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOVASTATIN PLUS NICOTINIC ACID; MEVINOLIN; NICOTINIC ACID; NICOTINIC RECEPTOR; PRAVASTATIN; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN; VITAMIN;

ACANTHOSIS NIGRICANS; ADIPOSE TISSUE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; DIABETES MELLITUS; DOSE RESPONSE; DRUG FORMULATION; DRUG RELEASE; DRY SKIN; DYSLIPIDEMIA; EMOTIONAL STRESS; FATTY ACID BLOOD LEVEL; FLUSHING; GASTROINTESTINAL SYMPTOM; HEART MUSCLE METABOLISM; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MYOPATHY; NONHUMAN; PANCREATITIS; PRIORITY JOURNAL; RETINA EDEMA; REVIEW; RISK FACTOR; SIDE EFFECT; STOMACH ACID SECRETION; TACHYPHYLAXIS; URIC ACID BLOOD LEVEL;

ADIPOSE TISSUE; ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; CORONARY DISEASE; FATTY ACIDS, NONESTERIFIED; FIBRINOLYSIS; FLUSHING; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, HDL; NIACIN; URIC ACID;

EID: 22644437126     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2005.01528.x     Document Type: Review

References (103)

1. Altschul R, Herman IH. Influence of oxygen inhalation on cholesterol metabolism. Arch Biochem 1954; 51: 308-9.
2. Altschul R. Die Beeinflussung des Blutcholesterinspiegels und der experimentellen Atherosklerose durch Nikotinsaure. Ztschr f Kr 3islaufforsch 1956; 45: 453-60.
3. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 1955; 54: 558-9.
4. Carlson LA. Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro. Acta Med Scand 1963; 173: 719-22.
5. Carlson LA, Orö L. The effect of nicotinic acid on the plasma free fatty acids. Acta Med Scand 1962; 172: 641-5.
6. Lorenzen A, Stannek C, Lang H et al. Characterization of a G protein-coupled receptor for nicotinic acid. Mol Pharmacol 2001; 59: 349-57.
7. Wise A, Foord SM, Fraser NJ et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003; 278: 9869-74.
8. Tunaru S, Kero J, Schaub A et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its antilipolytic effect. Nat Med 2003; 9: 352-5.
9. Carlson LA. The broad spectrum hypolipidaemic drug nicotinic acid. J Drug Dev 1990; 3 (Suppl. 1): 223-6.
10. Parsons WB, Achor RWP, Berge KG, McKenzie BF, Barker NW. Changes in blood lipids following prolonged administration of large doses of nicotinic acid to persons with hypercholesterolaemia. Proc Mayo Clin 1956; 31: 377.
11. Parsons WB, Flinn JH. Reduction of serum cholesterol levels and beta-lipoprotein cholesterol levels by nicotinic acid. Arch Intern Med 1959; 103: 783-90.
12. Dole VP. A relation between non-esterified fatty acids in plasma and the metabolism of glucose. J Clin Invest 1956; 35: 150-4.
13. Gordon RS Jr, Cherkes A. Unesterified fatty acids in human blood plasma. J Clin Invest 1956; 35: 206-12.
14. 14 as esterified fatty acid in the plasma of rats and turnover rate of plasma triglycerides. Acta Physiol Scand 1959; 47: 218-23.
15. 14 into liver and plasma lipids in man. Acta Soc Med Ups 1960; 65: 85-9.
16. Havel RJ. Conversion of plasma free fatty acids into triglycerides of plasma lipoprotein fractions in man. Metab Clin Exp 1961; 10: 1031-6.
17. Carlson LA, Orö L, Östman J. Effect of a single dose of nicotinic acid on plasma lipids in patients with hyperlipoproteinaemia. Acta Med Scand 1968; 183: 457-65.
18. Carlson LA, Orö L. Persistence of the inhibitory effect of nicotinic acid on catecholamine stimulated lipid mobilization during prolonged treatment with nicotinic acid. J Atheroscler Res 1965; 5: 436-9.
19. 3H-labelled nicotinic acid studied by autoradiography. Life Sci 1964; 3: 867-71.
20. Karpe F, Frayn KN. The nicotinic acid receptor - a new mechanism for an old drug. Lancet 2004; 363: 1892-4.
21. Havel RJ, Carlson LA, Ekelumd L-G, Holmgren A. Studies on the relation between mobilization of free fatty acids and energy metabolism in man: effects of norepinephrine and nicotinic acid. Metabolism 1964; 13: 1402-12.
22. Carlson LA, Lassers BW, Wahlqvist ML, Kaijser L. The relationship in man between plasma free fatty acids and myocardial metabolism of carbohydrate substrates. Cardiology 1972; 57: 51-4.
23. Lassers BW, Wahlqvist ML, Kaijser L, Carlson LA. Effect of nicotinic acid on myocardial metabolism in man at rest and during exercise. J Appl Physiol 1972; 33: 72-80.
24. Carlson LA, Fröberg SO, Nye ER. Acute effects of nicotinic acid on plasma, liver, heart and muscle lipids. Nicotinic acid in the rat. II. Acta Med Scand 1966; 180: 571-9.
25. Carlson LA, Levi L, Orö L. Plasma lipid and urinary excretion of catecholamines during experimentally induced emotional stress, and their modification by nicotinic acid. J Clin Invest 1968; 47: 1795-805.
26. Laurell S. Plasma free fatty acids in diabetic acidosis and starvation. Scand J Clin Lab Invest 1956; 8: 81-2.
27. Bierman E, Dole BP, Roberts TN. An abnormality in nonesterified fatty acid metabolism in diabetes mellitus. Diabetes 1957; 6: 475-9.
28. Ford CR, Stevens R, Bolinger R et al. Turnover of palmitate C-14 in diabetics and normals. Proc Soc Exp Biol Med 1963; 113: 177-9.
29. Carlson LA. Lecture for the 1968 Minkowski Award. Antilipolysis as a tool in the study of clinical and experimental diabetes. Diabetologia 1969; 5: 262-9.
30. Randle PJ, Garland PB, Hies CN et al. The glucose-fatty acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; I: 785-9.
31. Shah P, Veil A, Basu A et al. Elevated free fatty acids impair glucose metabolism in women. Diabetes 2003; 52: 38-42.
32. Staehr P, Hother-Nielsen O, Landau BR et al. Effects of free fatty acids per se on glucose production, gluconeogenesis and glycogenolysis. Diabetes 2003; 52: 260-7.
33. Carlson LA, Freyschuss U, Östman J. Suppression of splanchnic ketone body production in man by nicotinic acid. Diabetologia 1967; 3: 494-9.
34. Gross RC, Carlson LA. Metabolic effects of nicotinic acid in acute insulin deficiency in the rat. Diabetes 1968; 17: 353-61.
35. Fredrickson DA, Levy RI, Lees RS. Fat transport in lipoproteins: an integrated approach to mechanisms and disorders. N Engl J Med 1967; 276: 34-44, 94-103, 148-56, 215-25, 273-81.
36. Beaumont JL, Carlson LA, Cooper GR, Fejfar Z, Fredrickson DS. Classification of hyperlipidemias and hyper lipoproteinemias. Bull WHO 1970; 43: 891-915.
37. Carlson LA, Orö L. Effect of treatment with nicotinic acid for one month on serum lipids in patients with different types of hyperlipidaemia. Atherosclerosis 1973; 18: 1-9.
38. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345-53.
39. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III); final report. Circulation 2002; 106: 3143-421.
40. Albrink M, Man EB. Serum triglycerides in coronary artery disease. Arch Intern Med 1959; 103: 4-8.
41. Carlson LA. Serum lipids in men with myocardial infarction. Acta Med Scand 1960; 167: 399-413.
42. Miller GJ, Miller NE. Plasma high-density lipoprotein concentration and development of ischaemic heart disease. Lancet 1975; I: 16-9.
43. Castelli W. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992; 70: 3H-9H.
44. Gordon T, Castelli WP, Hjortland MC et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707-14.
45. Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidaemia. J Lipid Res 1993; 34: 295-308.
46. Lamarche B, Tchernof A, Dagenais GR et al. Small, dense LDL particle and the risk of ischemic heart disease: prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95: 69-75.
47. Superko HR, McGovern ME, Raul E et al. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I. Am J Cardiol 2004; 94: 588-94.
48. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989; 226: 271-6.
49. Von Eckardstein A, Assman G. Clinical implications of elevated lipoprotein (a). Curr Atheroscler Rep 2001; 3: 267-70.
50. Berglund L. Diet and drug therapy for lipoprotein (a). Curr Opin Lipidol 1995; 6: 48-56.
51. U.K. Prospective Diabetes Study Group. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care 1997; 20: 1683-7.
52. Elam MB, Hunninghake DB, Davis KE et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: a randomized trial. JAMA 2000; 284: 1263-70.
53. Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583-92.
54. Gotto AM, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease. J Am Coll Cardiol 2004; 43: 717-24.
55. Chapman MJ, Assman G, Fruchart J-C et al. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004; 20: 1253-68.
56. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 2004; 344: 1383-9.
57. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 260: 7-22.
58. Öst C-R, Sténson S. Regression of atherosclerosis during nicotinic acid therapy: a study in man by means of repeated arteriographies. In: Altschul R, ed. Niacin in Vascular Disorders and Hyperlipemia. Fort Lauderdale, FL: Charles C Thomas, 1964; 245-62.
59. Blankenhorn DH, Nessim SA, Johnson RL et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary bypass grafts. JAMA 1987; 257: 3233-40.
60. Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-98.
61. Taylor AJ, Sullenberger LE, Lee HJ et al. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110: 3512-7.
62. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360-81.
63. Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients. Long-term benefits with niacin. J Am Coll Cardiol 1986; 81: 1245-55.
64. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223: 405-18.
65. Zhao XQ, Morese J, Chait A et al. Simvastatin plus niacin protect against atherosclerosis progression and clinical events in coronary artery disease patients with metabolic syndrome. J Am Coll Cardiol 2002; 39 (Suppl. A): 242A [abstract 1130-73].
66. Canner PL, Furberg CD, Terrin ML et al. Niacin decreases myocardial infarction and total mortality in patients with the metabolic syndrome: results from the Coronary Drug Project. J Am Coll Cardiol 2003; 40 (Suppl. A): 291A [abstract].
67. Carlson LA. Niaspan, the prolonged-release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug. Int J Clin Pract 2004; 58: 706-13.
68. Knopp RH, Alagona P, Davidson M et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998; 47: 1097-104.
69. Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002; 162: 1568-76.
70. Kaijser L, Eklund B, Olsson AG et al. Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med Biol 1979; 57: 114-7.
71. Carlson LA, Ekelund LG, Orö L. Clinical and metabolic effects of different doses of prostaglandin E1 in man. Acta Med Scand 1968; 183: 423-30.
72. Olsson AG, Carlson LA, Anggard E et al. Prostacyclin production augmented in the short term by nicotinic acid. Lancet 1983; 2: 565.
73. Morrow JD, Parsons WG III, Roberts LJ et al. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 1989; 38: 263-74.
74. Rubenfire M for the Impact of Medical Subspeciality on Patient Compliance to Treatment (IMPACT) Study Group. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the impact of medical subspeciality on patient compliance to treatment (IMPACT) study. Am J Cardiol 2004; 41: 306-11.
75. Andersson S, Carlson LA, Orö L et al. Effect of nicotinic acid on gastric secretion of acid in human subjects and in dogs. Scand J Gastroenterol 1971; 6: 555-9.
76. Brinton EA, Eisenberg S, Breslow JL. Human HDL cholesterol levels are determined by apo A-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Arterioscler Thromb 1994; 14: 707-20.
77. Jin F-Y, Kmanna VS, Kashyap ML et al. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Arterioscler Thromb Vasc Biol 1997; 17: 2020-8.
78. Assman G, Schulte H, von Eckardstein A et al. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124(Suppl.): S11-20.
79. Gordon DJ, Probstfield JL, Garrison LJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.
80. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-8.
81. Robins SJ, Collins D, Wittes JT et al. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled study. JAMA 2001; 285: 1585-91.
82. Carlson LA. Effect of a single infusion of recombinant human proapolipoprotein A-I liposomes (synthetic HDL) on plasma lipoproteins in patients with low high-density lipoprotein cholesterol. Nutr Metab Cardiovasc Dis 1995; 5: 85-91.
83. Eriksson M, Carlson LA, Miettinen T et al. Stimulation of fecal steroid excretion after infusion of recombinant pro-apolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation 1999; 100: 594-8.
84. Nissen SE, Tsunoda T, Tuzcu EM et al. Effect of recombinant apo A-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290: 2292-300.
85. Westman J, Roobol C, Heymans C et al. Efflux of cholesterol from cholesterol loaded macrophages by incubation with synthetic HDL-particles. Scand J Clin Lab Invest 1993; 53: 773-82.
86. Weiner M, Redisch W, Steele JM. Occurrence of fibrinolytic activity following administration of nicotinic acid. Proc Soc Exp Biol Med 1958; 98: 755-7.
87. Brown SL, Sobel BE, Fujii S. Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis. Circulation 1995; 92: 767-72.
88. Hamsten A, Wiman B, de Faire U et al. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-63.
89. Hamsten A, de Faire U, Walldius G et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; ii: 3-9.
90. Asplund-Carlson A, Hamsten A, Wiman B et al. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL-triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia 1993; 36: 817-25.
91. Johansson JO, Egberg N, Asplund-Carlson A et al. Nicotinic acid treatment shifts the fibrinolytic balance favourably and decreases plasma fibrinogen in hypertriglyceridaemic men. J Cardiovasc Risk 1997; 4: 165-71.
92. Chesney CM, Elam MB, Herd JA et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). Am Heart J 2000; 140: 631-6.
93. Guyton JR, Blazing MA, Hagar J et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch Intern Med 2000; 160: 1177-84.
94. Rubic T, Trottman M, Lorenz RL. Stimulation of CD 36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Eiochem Pharmacol 2004; 67: 411-9.
95. Carlson LA, Riccardi G. Clinician's Manual on Diabetic Dyslipidaemia. London, UK: Science Press, 2004.
96. Jacobson TA, Chin MM, Fromell GJ. Fluvastatin with and without niacin for hypercholesterolemia. Am Cardiol 1994; 74: 149-54.
97. O'Keefe JH Jr. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol 1995; 76: 480-4.
98. Gardner SF. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. Pharmacotherapy 1996; 16: 419-23.
99. Guyton JR, Capuzzi DM. Treatment of hyperlipiemia with combined niacin-statin regimens. Am J Cardiol 1998; 82: 82U-6U.
100. Kashyap ML, McGovern ME, Berra K et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002; 89: 672-8.
101. Bays HE, Dujovne CA, McGovern ME et al. Comparison of once-daily niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin [the ADvicor Versus Other Cholesterolmodulating Agents Trial Evaluation (ADVOCATE)]. Am J Cardiol 2003; 91: 667-72.
102. Capuzzi DM, Morgan JM, Weiss RJ et al. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol 2003; 91: 1304-10.
103. Hunninghake DB, McGovern ME, Koren M et al. A dose-ranging study of a new, once daily, dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol 2003; 26: 112-8.